<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016327</url>
  </required_header>
  <id_info>
    <org_study_id>CDCA-354-001</org_study_id>
    <nct_id>NCT01016327</nct_id>
  </id_info>
  <brief_title>Study of NMS-1116354 in Solid Tumors</brief_title>
  <official_title>A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerviano Medical Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerviano Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase&#xD;
      inhibitor, in adult patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinuation of clinical investigation with NMS-1116354&#xD;
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose (MTD)</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics: plasma concentration at different times after dosing, area under the curve (AUC), maximum plasma concentration (Cmax), time of occurence of Cmax (tmax) and half-life (tÂ½)</measure>
    <time_frame>Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NMS-1116354</intervention_name>
    <description>Oral daily administration for 7 consecutive days every 14 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Advanced/metastatic solid tumors, for which no alternative effective standard therapy&#xD;
             is available&#xD;
&#xD;
          2. Maximum of 4 regimens of prior cancer therapy allowed&#xD;
&#xD;
          3. Prior radiotherapy allowed if no more than 25% of BM reserve irradiated&#xD;
&#xD;
          4. Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer&#xD;
             therapy&#xD;
&#xD;
          5. ECOG performance status (PS) 0 or 1&#xD;
&#xD;
          6. Adult (age &gt;/= 18 and &lt;/= 80 years) patients&#xD;
&#xD;
          7. Adequate renal, liver and BM reserve&#xD;
&#xD;
          8. Capability to swallow capsules intact&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current enrollment in another therapeutic clinical trial&#xD;
&#xD;
          2. Known brain metastases&#xD;
&#xD;
          3. Currently active second malignancy&#xD;
&#xD;
          4. Major surgery within 4 weeks prior to treatment&#xD;
&#xD;
          5. Any of the following in the past 6 months: myocardial infarction, unstable angina,&#xD;
             coronary/peripheral artery bypass graft, symptomatic congestive heart failure,&#xD;
             cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein&#xD;
             thrombosis&#xD;
&#xD;
          6. Pregnancy or breast-feeding women&#xD;
&#xD;
          7. Known active infections&#xD;
&#xD;
          8. Gastrointestinal disease or other malabsorption syndromes that would impact on drug&#xD;
             absorption&#xD;
&#xD;
          9. Adrenal insufficiency&#xD;
&#xD;
         10. Other severe acute or chronic medical or psychiatric condition that could compromise&#xD;
             protocol objectives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos Papadopoulos, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Texas Accelerated Research Therapeutics (START)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Laffranchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nerviano Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefania Crippa, Biotech D, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nerviano Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I study</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Cdc7 kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

